PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
ZVRA Zevra Therapeutics
- 8.070
- +0.080+1.00%
Close Feb 14 16:00 ET
- 8.090
- +0.020+0.25%
Post 19:31 ET
430.74MMarket Cap-3.79P/E (TTM)
8.210High7.930Low348.86KVolume8.000Open7.990Pre Close2.81MTurnover0.82%Turnover RatioLossP/E (Static)53.38MShares9.76052wk High6.17P/B344.60MFloat Cap4.20052wk Low--Dividend TTM42.70MShs Float418.400Historical High--Div YieldTTM3.50%Amplitude2.560Historical Low8.064Avg Price1Lot Size
About Zevra Therapeutics Company
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Company Profile
SymbolZVRA
Company NameZevra Therapeutics
Listing DateApr 16, 2015
Founded2006
CEOMr. Neil F. McFarlane, M.S.
MarketNASDAQ
Employees69
Fiscal Year Ends12-31
Address1180 Celebration Boulevard,Suite 103
CityCelebration
ProvinceFlorida
CountryUnited States of America
Zip Code34747
Phone1-321-939-3416
Websitehttp://zevra.com
Company Executives
- Name
- Position
- Salary
- Neil F. McFarlane, M.S.
- Director, President and Chief Executive Officer
- 3.45M
- Dr. Adrian Quartel, M.D.
- Chief Medical Officer
- --
- R. LaDuane Clifton, C.P.A.,M.B.A.
- Chief Financial Officer, Secretary and Treasurer
- 2.26M
- Joshua Schafer, M.B.A.
- Chief Commercial Officer and Executive Vice President, Business Development
- 1.82M
- Timothy J. Sangiovanni
- Senior Vice President, Corporate Controller and Principal Accounting Officer
- --
- Tamara A. Favorito
- Chairman of the Board
- 324.39K
- Dr. Alvin Shih, M.D.
- Director
- --
- Corey Watton
- Independent Director
- 260.67K
- Douglas W. Calder
- Independent Director
- 258.02K
- Dr. Wendy L. Dixon, PhD
- Independent Director
- 274.00K
- Thomas Anderson
- Independent Director
- 243.04K
- John B. Bode
- Independent Director
- 264.31K
Trending Stocks
Discussing
Major earnings are approaching! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Popular on moomoo
Feb 13 17:34
China's asset revaluation sparks debate: What are mooers buying?